Harness High-Quality PBPK Modeling To Enhance Preclinical And Clinical Readiness

Source: Lonza

By Deanna Mudie, Ph.D., Senior Principal Engineer, Lonza Small Molecules, and John DiBella, President, SLP Division, Simulations Plus

Scientist in lab GettyImages-872025342

Rapid and efficient development of drug candidates sits top of mind for pharmaceutical companies with funding constraints looking to accelerate timelines. Unfortunately, many early drug candidates demonstrate poor oral absorption properties, which can make it challenging to achieve target pharmacokinetic profiles. Without up-front knowledge of absorption risks and mitigation strategies, poor absorption can significantly impact preclinical and clinical study timelines and costs.

However, advancements in physiologically based pharmacokinetic (PBPK) modeling are making it easier than ever to identify and mitigate absorption risks in early drug development. A wide range of approved drugs have utilized PBPK modeling to develop safer, more effective formulations and eliminate unnecessary animal and human studies. Download the full article to learn more about how utilizing PBPK modeling in your early development studies can help you identify drug absorption risks, formulate risk mitigation strategies, and de-risk your preclinical and clinical study outcomes.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Delivery Leader? Subscribe today.

Subscribe to Drug Delivery Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Delivery Leader